KRAS and neoplasm: Concerning the discordant results obtained during the validation process, any of the involved centers was able to authenticate the original mutation c.35G>C (p.G12A) reported by center 1 in KRAS. After performing re-test in both previous sections and a second isolation of DNA, the sample still resulted mutated, leading to tumor heterogeneity as a concluding interpretation of the case.